I-26: Surgical Techniques in Tissue Transplantation for Fertility Preservation

Background Ovarian tissue cryopreservation is an option for patients who require immediate gonagonadotoxic treatment of cancers. when there is insufficient time to conduct ovulation induction This procedure can be used in patients with genetic mutations with a high risk for premature ovarian failure.This strategy is the only option for fertility preservation in prepubertal girls or in women who have hormone-sensitive malignancies. prophylactically cryopreserve ovarian tissue can be used for hematopoietic stem cell transplantation for the treatment of benign hematologic diseases or autoimmune diseases that haven’t respond to immunosuppressive treatment. Ovarian tissue should be obtained before a woman initiates treatment. Obtaining a small volume of cortical tissue by a laparoscopic or minilaparotomy is the most common way to get ovarian tissue,then the tissue is transferred to the laboratory on ice and cut then cryopreserved. In cases in whom complete ovarian failure after treatment is anticipated, whole-ovary cryopreservation may be considered in these patients the whole ovary is removed with a large part of the vascular pedicle left attached. Both slow-freezing and vitrification can be used to cryopreserve in this situation. Autologous ovarian cortical tissue transplantation can be performed into orthotopic or heterotopic site. Orthotopic transplantation of ovarian tissue involves transplantation of strips of thawed ovarian tissue into either the medullary portion of the remaining ovary or the peritoneum of the ovarian fossa. Heterotopic transplantation of ovarian tissue has been reported in the forearm, abdominal wall, and chest wall. There is no report of a successful transplantation of a previously cryopreserved whole ovary in humans. blood-borne cancers have the highest of risk for malignancy following transplantation of ovarian tissue. whereas metastatic disease was less common in most other cancers. ovarian tissue transplantation is not recommended for patients with blood-borne malignancies or malignancies that metastasize to the ovary. MaterialsAndMethods N;Results N;Conclusion N;